This is the shift from scientific participation to genomic economic rights. For decades, the central question was whether underserved communities would be included in precision medicine. Today, another question demands attention: when our biological contributions help generate scientific discoveries, intellectual property, and commercial value, who benefits economically?
MCPM is advancing the Participant Genomic Rights and Economic Benefit Framework through national policy engagement, institutional discussions, and emerging biotechnology relationships. The objective is to explore practical models for informed consent, participant rights, responsible data governance, economic participation, and transparent community benefit-sharing.
This framework is a proposed initiative under development. It does not describe an enacted policy, and it does not assert that research participants hold intellectual property rights created through research.